Neurocrine Biosciences | GJELD



Debt Endring Dato
AbbVie USD 67.14B 3.94B 2024-12
Acadia Pharmaceuticals USD 0 0 2024-12
Agios Pharmaceuticals USD 0 0 2024-12
ALKERMES USD 0 366M 2024-12
Alnylam Pharmaceuticals USD 1.02B 967K 2024-12
Amgen USD 60.1B 299M 2024-12
Biogen USD 6.3B 1.9M 2024-12
BioMarin Pharmaceutical USD 596.24M 1.61M 2024-12
Cytokinetics USD 657.12M 1.1M 2024-12
Dynavax Technologies USD 223.85M 293K 2024-12
Exelixis USD 0 0 2025-01
Gilead Sciences USD 26.71B 3.46B 2024-12
Halozyme Therapeutics USD 1.51B 1.64M 2024-12
Incyte USD 37.96M 5.81M 2024-12
Intra Cellular Therapies USD 0 0 2024-12
Ionis Pharmaceuticals USD 1.25B 32.8M 2024-12
Neurocrine Biosciences USD 0 0 2024-12
Pfizer USD 64.35B 3.35B 2024-12
Prothena USD 0 0 2024-12
Regeneron Pharmaceuticals USD 2.7B 400K 2024-12
Repligen USD 521.61M 221.25M 2024-09
Sarepta Therapeutics USD 1.14B 90.44M 2024-12
Teva Pharmaceutical Industries USD 18.08B 901M 2024-12
Ultragenyx Pharmaceutical USD 0 0 2024-12
Vertex Pharmaceuticals USD 112.8M 1.2M 2024-12



Neurocrine Biosciences GJELD - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.